Coronary stents and non-cardiac surgery: to bridge or not to bridge?

References
1 Hamm CW, Bassand JP, Agewall S. et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). EurHeart J 2011; 32: 2999-3054.
2 Steg PG, James SK, Atar D. et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). EurHeart J 2012; 33: 2569-2619.
3 Windecker S, Kolh P, Alfonso F. et al. 2014 ESC/ EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). EurHeart J 2014; 35: 2541-2619.
4 Collet JP, Montalescot G, Blanchet B. et al. Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes. Circulation 2004; 110: 2361-2367.
5 Ferreira-Gonzalez I, Marsal JR, Ribera A. et al. Double antiplatelet therapy after drug-eluting stent implantation: risk associated with discontinuation within the first year. J Am Coll Cardiol 2012; 60: 1333-1339.
6 Berger PB, Kleiman NS, Pencina MJ. et al. Frequency of major noncardiac surgery and subsequent adverse events in the year after drug-eluting stent placement results from the EVENT (Evaluation of Drug-Eluting Stents and Ischemic Events) Registry. JACC Cardiovasc Interv 2010; 03: 920-927.
7 Rossini R, Capodanno D, Lettieri C. et al. Prevalence, predictors, and long-term prognosis of premature discontinuation of oral antiplatelet therapy after drug eluting stent implantation. Am J Cardiol 2011; 107: 186-194.
8 Rossini R, Musumeci G, Capodanno D. et al. Peri-operative management of oral antiplatelet therapy and clinical outcomes in coronary stent patients undergoing surgery. Results of a multicentre registry. Thromb Haemost 2015; 113: 272-282.
9 Devereaux PJ, Mrkobrada M, Sessler DI. et al. Aspirin in patients undergoing noncardiac surgery. N Engl J Med 2014; 370: 1494-1503.
10 Hansson EC, Rexius H, Dellborg M. et al. Coronary artery bypass grafting-related bleeding complications in real-life acute coronary syndrome patients treated with clopidogrel or ticagrelor. Eur J Cardiothorac Surg 2014; 46: 699-705.
11 Grove EL, Hossain R, Storey RF. Platelet function testing and prediction of procedural bleeding risk. Thromb Haemost 2013; 109: 817-824.
12 Kristensen SD, Knuuti J, Saraste A. et al. 2014 ESC/ ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur Heart J 2014; 35: 2383-2431.
13 Mehran R, Baber U, Steg PG. et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet 2013; 382: 1714-1722.
14 Parolari A, Mussoni L, Frigerio M. et al. Increased prothrombotic state lasting as long as one month after on-pump and off-pump coronary surgery. J Thorac Cardiovasc Surg 2005; 130: 303-308.
15 Modrau IS, Wurtz M, Kristensen SD. et al. Reduced Effect of Aspirin and Clopidogrel Following Hybrid Coronary Revascularization. Clin Appl Thromb Hemost. 2015 Epub ahead of print.
16 De Luca G, Dirksen MT, Spaulding C. et al. Time course, predictors and clinical implications of stent thrombosis following primary angioplasty. Insights from the DESERT cooperation. Thromb Haemost 2013; 110: 826-833.
17 Armstrong EJ, Sab S, Singh GD. et al. Predictors and outcomes of recurrent stent thrombosis: results from a multicenter registry. JACC Cardiovasc Interv 2014; 07: 1105-1113.
18 Capodanno D, Angiolillo DJ. Management of anti-platelet therapy in patients with coronary artery disease requiring cardiac and noncardiac surgery. Circulation 2013; 128: 2785-2798.
19 Kristensen SD, Wurtz M, Grove EL. et al. Contemporary use of glycoprotein IIb/IIIa inhibitors. Thromb Haemost 2012; 107: 215-224.
20 Savonitto S, Caracciolo M, Cattaneo M. et al. Management of patients with recently implanted coronary stents on dual antiplatelet therapy who need to undergo major surgery. J Thromb Haemost 2011; 09: 2133-2142.
21 Rassi AN, Blackstone E, Militello MA. et al. Safety of “bridging” with eptifibatide for patients with coronary stents before cardiac and non-cardiac surgery. Am J Cardiol 2012; 110: 485-490.
22 Warshauer J, Patel VG, Christopoulos G. et al. Outcomes of preoperative bridging therapy for patients undergoing surgery after coronary stent implantation: a weighted meta-analysis of 280 patients from eight studies. Catheter Cardiovasc Interv 2015; 85: 25-31.
23 Angiolillo DJ, Firstenberg MS, Price MJ. et al. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. J Am Med Assoc 2012; 307: 265-274.
24 Omran H, Bauersachs R, Rubenacker S. et al. The HAS-BLED score predicts bleedings during bridging of chronic oral anticoagulation. Results from the national multicentre BNK Online bRiDging REgistRy (BORDER). Thromb Haemost 2012; 108: 65-73.
25 Capodanno D, Musumeci G, Lettieri C. et al. Impact of Bridging with Perioperative Low-Molecular Weight Heparin on Cardiac and Bleeding Outcomes of Stented Patients Undergoing Non-Cardiac Surgery. Thromb Haemost 2015; 114: 423-431.
26 Limantoro I, Pisters R. Peri-procedural antithrombotic bridging and the assessment of the associated risk of major bleeding. Thromb Haemost 2012; 108: 9-10.
27 Spyropoulos AC. Pro: “Bridging anticoagulation is needed during warfarin interruption in patients who require elective surgery”. Thromb Haemost 2012; 108: 213-216.
28 Douketis JD. Contra: “Bridging anticoagulation is needed during warfarin interruption when patients require elective surgery”. Thromb Haemost 2012; 108: 210-212.
29 Douketis JD, Healey JS, Brueckmann M. et al. Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trial. Thromb Haemost 2015; 113: 625-632.